請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/21248
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 莊雅惠(Ya-Hui Chuang) | |
dc.contributor.author | Yu-Wen Wang | en |
dc.contributor.author | 王禹文 | zh_TW |
dc.date.accessioned | 2021-06-08T03:29:28Z | - |
dc.date.copyright | 2019-08-26 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-08-15 | |
dc.identifier.citation | 1. Kaplan, M.M., et al., Primary biliary cirrhosis. N Engl J Med, 2005. 353(12): p. 1261-1273.
2. Beuers, U., et al., Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. Hepatology, 2015. 62(5): p. 1620-2. 3. Boonstra, K., et al., Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol, 2012. 56(5): p. 1181-1188. 4. Bergasa, N.V., Pruritus and fatigue in primary biliary cirrhosis. Clin Liver Dis, 2003. 7(4): p. 879-900. 5. Bowlus, C.L. et al., The diagnosis of primary biliary cirrhosis. Autoimmun Rev, 2014. 13(4-5): p. 441-4. 6. Hirschfield, G.M., et al., The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol, 2013. 8: p. 303-30. 7. Harada, K., et al., Molecular mechanisms of cholangiopathy in primary biliary cirrhosis. Med Mol Morphol, 2006. 39(2): p. 55-61. 8. Bowlus, C.L., et al., Primary biliary cholangitis: medical and specialty pharmacy management update. J Manag Care Spec Pharm,, 2016. 22(10-as Suppl): p. S3-S15. 9. Selmi, C., et al., Innate immunity and primary biliary cirrhosis. Curr Mol Med, 2009. 9(1): p. 45-51. 10. Schwabe, R.F., et al., Toll-like receptor signaling in the liver. Gastroenterology, 2006. 130(6): p. 1886-1900. 11. Mao, T.K., et al., Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. Hepatology, 2005. 42(4): p. 802-8. 12. Chuang, Y.H., et al., Increased killing activity and decreased cytokine production in NK cells in patients with primary biliary cirrhosis. J Autoimmun, 2006. 26(4): p. 232-40. 13. Shimoda, S., et al., Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology, 2011. 53(4): p. 1270-81. 14. Ambrosini, Y.M., et al., The multi-hit hypothesis of primary biliary cirrhosis: polyinosinic-polycytidylic acid (poly I:C) and murine autoimmune cholangitis. Clin Exp Immunol, 2011. 166(1): p. 110-20. 15. Gershwin, M., et al., Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol, 1987. 138(10): p. 3525-3531. 16. Coppel, R.L., et al., Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase. Proc Natl Acad Sci U S A, 1988. 85(19): p. 7317-7321. 17. Szostecki, C., et al., Autoantibodies to the nuclear Sp100 protein in primary biliary cirrhosis and associated diseases: epitope specificity and immunoglobulin class distribution. Scand J Immunol, 1992. 36(4): p. 555-564. 18. Van De Water, J., et al., Evidence for the targeting by 2-oxo-dehydrogenase enzymes in the T cell response of primary biliary cirrhosis. J Immunol, 1991. 146(1): p. 89-94. 19. Van de Water, J., et al., Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis. J Exp Med, 1995. 181(2): p. 723-733. 20. Löhr, H., et al., Autoreactive liver-infiltrating T cells in primary biliary cirrhosis recognize inner mitochondrial epitopes and the pyruvate dehydrogenase complex. J Hepatol, 1993. 18(3): p. 322-327. 21. Leon, M.P., et al., Immunogenicity of biliary epithelium: investigation of antigen presentation to CD4+ T cells. Hepatology, 1996. 24(3): p. 561-567. 22. Hasimoto, E., et al. Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis. in Mayo Clinic Proceedings. 1993. Elsevier. 23. Nagano, T., et al., Cytokine profile in the liver of primary biliary cirrhosis. J Clin Immunol, 1999. 19(6): p. 422-427. 24. Lan, R.Y., et al., Liver‐targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology, 2006. 43(4): p. 729-737. 25. Chuang, Y.H., et al.. The immunopathology of human biliary cell epithelium. in Semi immunopathol. 2009. Springer. 26. Chen, X.M., et al., The immunobiology of cholangiocytes. Immunology and cell biology, 2008. 86(6): p. 497. 27. Harada, K., et al., Lipopolysaccharide activates nuclear factor-kappaB through toll-like receptors and related molecules in cultured biliary epithelial cells. Lab Investig, 2003. 83(11): p. 1657. 28. Morland, C.M., et al., Promotion of leukocyte transendothelial cell migration by chemokines derived from human biliary epithelial cells in vitro. Proc Assoc Am Physicians, 1997. 109(4): p. 372-382. 29. Bloom, S., et al., Adhesion molecule expression in primary sclerosing cholangitis and primary biliary cirrhosis. Gut, 1995. 36(4): p. 604-609. 30. Tinmouth, J., et al., Apoptosis of biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. Liver, 2002. 22(3): p. 228-234. 31. Harada, K., et al., Cell‐kinetic study of proliferating bile ductules in various hepatobiliary diseases. Liver, 1998. 18(4): p. 277-284. 32. Harada, K., et al., Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis. Hepatology, 1997. 26(6): p. 1399-1405. 33. Lleo, A., et al., Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology, 2010. 52(3): p. 987-98. 34. Invernizzi, P., et al., From bases to basis: linking genetics to causation in primary biliary cirrhosis. Clin Gastroenterol Hepatol, 2005. 3(5): p. 401-410. 35. Selmi, C., et al., Genes and (auto) immunity in primary biliary cirrhosis. Genes Immun, 2005. 6(7): p. 543. 36. Hirschfield, G.M., et al., Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med, 2009. 360(24): p. 2544-2555. 37. Van de Water, J., et al., Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest, 1993. 91(6): p. 2653-2664. 38. Selmi, C., et al., Bacteria and human autoimmunity: the case of primary biliary cirrhosis. Curr Opin Rheumatol, 2004. 16(4): p. 406-410. 39. Long, S.A., et al., Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis. J Immunol, 2001. 167(5): p. 2956-2963. 40. Amano, K., et al., Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. J Immunol, 2005. 174(9): p. 5874-5883. 41. Leung, P.S.C., et al., Immunization with a xenobiotic 6-bromohexanoate bovine serum albumin conjugate induces antimitochondrial antibodies. J Immunol, 2003. 170(10): p. 5326-5332. 42. Rieger, R., et al., Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun, 2006. 27(1): p. 7-16. 43. West, T., Esters of acetylenic carboxylic acid. Synthetic Perfumes, Their Chemistry and Preparation, 1949. 241. 44. Opdyke, D., Monographs on fragrance raw materials. Food Chem Toxicol, 1980. 18(6): p. 649-681. 45. Winter, R., Methyl heptine carbonate. 1989, Crown Publishers, New York. p. 158. 46. Rieger, R., et al., The X and why of xenobiotics in primary biliary cirrhosis. J Autoimmun, 2007. 28(2-3): p. 76-84. 47. Smyk, D.S., et al., Urinary tract infection as a risk factor for autoimmune liver disease: from bench to bedside. Clin Res Hepatol Gastroenterol, 2012. 36(2): p. 110-121. 48. Bogdanos, D.P., et al., Primary biliary cirrhosis is characterized by IgG3 antibodies cross‐reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology, 2005. 42(2): p. 458-465. 49. Kim, W.R., et al., Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology, 2000. 119(6): p. 1631-1636. 50. Invernizzi, P., et al., Frequency of monosomy X in women with primary biliary cirrhosis. The Lancet, 2004. 363(9408): p. 533-535. 51. Miozzo, M., et al., Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology, 2007. 46(2): p. 456-462. 52. Lleo, A., et al., Y chromosome loss in male patients with primary biliary cirrhosis. J Autoimmun, 2013. 41: p. 87-91. 53. Alvaro, D., et al., Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis. J Hepatol, 2004. 41(6): p. 905-912. 54. Gershwin, M.E., et al., Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview‐based study of 1032 patients. Hepatology, 2005. 42(5): p. 1194-1202. 55. Lozupone, C.A., et al., Diversity, stability and resilience of the human gut microbiota. Nature, 2012. 489(7415): p. 220-30. 56. Fukuda, S., et al., Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature, 2011. 469(7331): p. 543. 57. Rowland, I., et al., Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr, 2017: p. 1-24. 58. Round, J.L., et al., The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol, 2009. 9(5): p. 313-23. 59. Rothschild, D., et al., Environment dominates over host genetics in shaping human gut microbiota. Nature, 2018. 555(7695): p. 210. 60. Thaiss, C.A., et al., The microbiome and innate immunity. Nature, 2016. 535(7610): p. 65. 61. Vijay-Kumar, M., et al., Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science, 2010: p. 1179721. 62. Henao-Mejia, J., et al., Inflammasomes and metabolic disease. Annu Rev Physiol, 2014. 76: p. 57-78. 63. Zheng, Y., et al., Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nature medicine, 2008. 14(3): p. 282. 64. Nieuwenhuis, E.E., et al., Cd1d-dependent regulation of bacterial colonization in the intestine of mice. J Clin Invest, 2009. 119(5): p. 1241-1250. 65. Org, E., et al., Genetic and environmental control of host-gut microbiota interactions. Genome Res, 2015. 25(10): p. 1558-1569. 66. Zmora, N., et al., You are what you eat: diet, health and the gut microbiota. Nat Rev Gastroenterol Hepatol, 2018: p. 1. 67. Schmidt, B., et al., Establishment of Normal Gut Microbiota Is Compromised under Excessive Hygiene Conditions. PloS one, 2011. 6(12): p. e28284. 68. Jin, Y., et al., Effects of environmental pollutants on gut microbiota. Environ Pollut, 2017. 222: p. 1-9. 69. Lu, K., et al., Xenobiotics: Interaction with the Intestinal Microflora. Ilar j, 2015. 56(2): p. 218-27. 70. Belkaid, Y., et al., Role of the microbiota in immunity and inflammation. Cell, 2014. 157(1): p. 121-41. 71. Levy, M., et al., Dysbiosis and the immune system. Nat Rev Immunol, 2017. 17(4): p. 219-232. 72. Levy, M., et al., Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell, 2015. 163(6): p. 1428-1443. 73. Maekawa, T., et al., Porphyromonas gingivalis manipulates complement and TLR signaling to uncouple bacterial clearance from inflammation and promote dysbiosis. Cell Host Microbe, 2014. 15(6): p. 768-778. 74. Moon, C., et al., Vertically transmitted faecal IgA levels determine extra-chromosomal phenotypic variation. Nature, 2015. 521(7550): p. 90. 75. Gevers, D., et al., The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe, 2014. 15(3): p. 382-392. 76. Frank, D.N., et al., Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A, 2007. 104(34): p. 13780-13785. 77. Di Cagno, R., et al., Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization. BMC Microbiol, 2011. 11(1): p. 219. 78. Wu, H.J., et al., Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity, 2010. 32(6): p. 815-827. 79. Risnes, K.R., et al., Antibiotic exposure by 6 months and asthma and allergy at 6 years: findings in a cohort of 1,401 US children. Am J Epidemiol, 2010. 173(3): p. 310-318. 80. Berg, R.D., Bacterial translocation from the gastrointestinal tract, in Mechanisms in the Pathogenesis of Enteric Diseases 2. 1999, Springer. p. 11-30. 81. Berg, R.D., et al., Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun, 1979. 23(2): p. 403-411. 82. Kiziltas, S., Toll-like receptors in pathophysiology of liver diseases. World J Hepatol, 2016. 8(32): p. 1354. 83. Li, Y., et al., Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Autoimmun Rev, 2017. 16(9): p. 885-896. 84. Long, S.L., et al., Interactions between gut bacteria and bile in health and disease. Mol Aspects Med, 2017. 56: p. 54-65. 85. Rizzetto, L., et al., Connecting the immune system, systemic chronic inflammation and the gut microbiome: the role of sex. J Autoimmun, 2018. 92: p. 12-34. 86. Tang, R., et al., Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut, 2018. 67(3): p. 534-541. 87. Koarada, S., et al., Genetic control of autoimmunity: protection from diabetes, but spontaneous autoimmune biliary disease in a nonobese diabetic congenic strain. J Immunol, 2004. 173(4): p. 2315-2323. 88. Oertelt, S., et al., Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-β receptor II dominant-negative mice. J Immunol, 2006. 177(3): p. 1655-1660. 89. Gorelik, L., et al., Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity, 2000. 12(2): p. 171-181. 90. Mattner, J., et al., Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe, 2008. 3(5): p. 304-315. 91. Wang, J.J., et al., Escherichia coli infection induces autoimmune cholangitis and anti-mitochondrial antibodies in non-obese diabetic (NOD).B6 (Idd10/Idd18) mice. Clin Exp Immunol, 2014. 175(2): p. 192-201. 92. Bogdanos, D.P., et al., Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol, 2004. 40(1): p. 31-39. 93. Wakabayashi, K., et al., Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology, 2008. 48(2): p. 531-540. 94. Wu, S.J., et al., Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. Hepatology, 2011. 53(3): p. 915-925. 95. Chang, C.H., et al., Innate immunity drives xenobiotic‐induced murine autoimmune cholangitis. Clin Exp Immunol, 2014. 177(2): p. 373-380. 96. Syu, B.J., et al., Dual roles of IFN-γ and IL-4 in the natural history of murine autoimmune cholangitis: IL-30 and implications for precision medicine. Sci Rep, 2016. 6: p. 34884. 97. Hsueh, Y.H., et al., AAV-IL-22 modifies liver chemokine activity and ameliorates portal inflammation in murine autoimmune cholangitis. J Autoimmun, 2016. 66: p. 89-97. 98. Chua, H.H., et al., Intestinal Dysbiosis Featuring Abundance of Ruminococcus gnavus Associates With Allergic Diseases in Infants. Gastroenterology, 2018. 154(1): p. 154-167. 99. Chang, C.H., et al., Innate immunity drives the initiation of a murine model of primary biliary cirrhosis. PloS one, 2015. 10(3): p. e0121320. 100. Tanaka, A., et al., Environmental basis of primary biliary cholangitis. Exp Biol Med, 2018. 243(2): p. 184-189. 101. Allina, J., et al., T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun, 2006. 27(4): p. 232-241. 102. Wiest, R., et al., Targeting the gut-liver axis in liver disease. J Hepatol, 2017. 67(5): p. 1084-1103. 103. Acharya, C., et al., Gut microbiota and complications of liver disease. Gastroenterol Clin North Am, 2017. 46(1): p. 155-169. 104. Lleo, A., et al., Evolving trends in female to male incidence and male mortality of primary biliary cholangitis. Sci Rep, 2016. 6: p. 25906. 105. Marschall, H.-U., et al., Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort. Sci Rep, 2019. 9(1): p. 1-8. 106. Ma, H.D., et al., Gut microbiota translocation promotes autoimmune cholangitis. J Autoimmun, 2018. 95: p. 47-57. 107. Schrumpf, E., et al., The gut microbiota contributes to a mouse model of spontaneous bile duct inflammation. J Hepatol, 2017. 66(2): p. 382-389. 108. Rogier, R., et al., Alteration of the intestinal microbiome characterizes preclinical inflammatory arthritis in mice and its modulation attenuates established arthritis. Sci Rep, 2017. 7(1): p. 15613. 109. Siddiqui, H., et al., Microbiological and bioinformatics analysis of primary Sjögren's syndrome patients with normal salivation. J Oral Microbiol, 2016. 8(1): p. 31119. 110. Castaner, O., et al., The gut microbiome profile in obesity: a systematic review. Int J Endocrinol, 2018. 2018. 111. Yang, T., et al., Gut dysbiosis is linked to hypertension. Hypertension, 2015. 65(6): p. 1331-1340. 112. Jeffery, I.B., et al., An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut, 2012. 61(7): p. 997-1006. 113. Hevia, A., et al., Intestinal dysbiosis associated with systemic lupus erythematosus. MBio, 2014. 5(5): p. e01548-14. 114. Mejía-León, M., et al., Diet, microbiota and immune system in type 1 diabetes development and evolution. Nutrients, 2015. 7(11): p. 9171-9184. 115. Ormerod, K.L., et al., Genomic characterization of the uncultured Bacteroidales family S24-7 inhabiting the guts of homeothermic animals. Microbiome, 2016. 4(1): p. 36. 116. Osaka, T., et al., Meta-analysis of fecal microbiota and metabolites in experimental colitic mice during the inflammatory and healing phases. Nutrients, 2017. 9(12): p. 1329. 117. Potempa, M., et al., Interpain A, a cysteine proteinase from Prevotella intermedia, inhibits complement by degrading complement factor C3. PLoS Pathog, 2009. 5(2): p. e1000316. 118. Lleo, A., et al., Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology, 2009. 49(3): p. 871-879. 119. Benias, P.C., et al., Hepatic expression of toll-like receptors 3, 4, and 9 in primary biliary cirrhosis and chronic hepatitis C. Clin Res Hepatol Gastroenterol, 2012. 36(5): p. 448-454. 120. Wang, A.P., et al., Hepatic expression of toll-like receptor 4 in primary biliary cirrhosis. J Autoimmun, 2005. 25(1): p. 85-91. 121. Yokoyama, T., et al., Human intrahepatic biliary epithelial cells function in innate immunity by producing IL‐6 and IL‐8 via the TLR4‐NF‐κB and‐MAPK signaling pathways. Liver Int, 2006. 26(4): p. 467-476. 122. Huang, Y.H., et al., Expression of toll-like receptors and type 1 interferon specific protein MxA in biliary atresia. Lab Investig, 2007. 87(1): p. 66. 123. Huang, Y.H., et al., Toll-like receptor 7 agonist induces hypoplasia of the biliary system in a neonatal mouse model. J Microbiol Immunol Infect, 2018. 51(2): p. 166-173. 124. Patel, T., et al., Dysregulation of apoptosis as a mechanism of liver disease: an overview. Semin Liver Dis, 1998. 18(2): p. 105-14. 125. Yuan, S., et al., Toll-like receptor 9 activation by CpG oligodeoxynucleotide 7909 enhances the radiosensitivity of A549 lung cancer cells via the p53 signaling pathway. Oncol Lett, 2018. 15(4): p. 5271-5279. 126. Rojas-Feria, M., et al., Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol, 2013. 19(42): p. 7327. 127. Kingham, J. and D. Parker, The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences. Gut, 1998. 42(1): p. 120-122. 128. Etienne-Mesmin, L., et al., Hepatocyte toll-like receptor 5 promotes bacterial clearance and protects mice against high-fat diet–induced liver disease. Cell Mol Gastroenterol Hepatol, 2016. 2(5): p. 584-604. 129. Wang, L., et al., Toll‐like receptor 5 signaling restrains T‐cell/natural killer T‐cell activation and protects against concanavalin A–induced hepatic injury. Hepatology, 2017. 65(6): p. 2059-2073. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/21248 | - |
dc.description.abstract | 原發性膽汁性膽管炎 (Primary biliary cholangitis;PBC) 為一好發於中年婦女之慢性肝臟自體免疫疾病,患者體內免疫細胞浸潤於門脈區並破壞肝臟末端小膽管,導致慢性膽汁鬱積。臨床上發病之女性人數為男性的十倍,除了導因於性染色體與性激素的差異,女性亦更常接觸清潔劑、保養品及化妝品而暴露於PBC潛在誘發因子下。此外,飲食、衛生條件及環境物質皆會影響腸內菌叢 (microbiota) 組成,當這些微生物的衍生物經肝門靜脈由腸道移動至肝臟後,被細胞上 pattern recognition receptors (PRRs) 辨認後,會啟動下游的免疫反應。本研究利用外源物誘發之小鼠模式探討PBC 疾病致病機轉。為了瞭解環境中外源物在PBC中的角色,我們讓兩種性別的小鼠暴露於等量的 2-OA-OVA 以誘發自體免疫性膽管炎並檢測其免疫反應,發現刺激十一週後公鼠與母鼠皆出現自體免疫性膽管炎症狀但母鼠門脈區淋巴球浸潤及發炎情形較公鼠嚴重。且在刺激三週時皆可測得小鼠膽管上皮細胞凋亡。接著,我們採集三週小鼠糞便分析腸內菌叢組成,發現致敏化後菌叢組成改變,其中,未致敏化的公鼠具較多保護性菌叢。我們也分析細胞上辨識腸內不同微生物的Toll-like receptors (TLR) 表現量,測得經致敏化的小鼠膽管中TLR7 與 TLR9顯著升高。最後,為了瞭解菌群組成改變在 PBC 疾病中的致病機轉,我們在誘發母鼠自體免疫性膽管炎前先餵食小鼠非致病性大腸桿菌株 (DH5α strain) 以干擾小鼠腸內菌,發現給予外源性細菌的小鼠五週後肝臟內浸潤的免疫細胞顯著升高且發炎情形嚴重,保護性的TLR5 表現量亦顯著降低。以上實驗結果顯示外源物刺激引起的腸內菌失衡會誘發膽管上皮細胞進行細胞凋亡,進而導致PBC的發生。 | zh_TW |
dc.description.abstract | Primary biliary cholangitis (PBC) is a chronic liver autoimmune disease characterized by immune-mediated destruction of the intrahepatic bile ducts. PBC presents a female predominance with almost 10:1. Aside from the impact of sex chromosome and sex hormones, female tend to experience greater exposure to chemicals such as detergents, facial care products, and cosmetics, which are potential triggers of PBC. Diets, personal hygiene, and environmental xenobiotics affect the gut microbiota. Products of gut microbiota circulate through the gut-liver axis and provoke immune responses in the liver. In the study, we investigated the mechanisms of PBC by the xenobiotic induced PBC mouse model. To investigate the role of environmental xenobiotics in PBC, we exposed mice of both genders to equivalent 2-octynoic acid conjugated to ovalbumin (2-OA-OVA) to induce autoimmune cholangitis and monitored their immune responses. The results showed that both male and female mice immunized with 2-OA-OVA developed autoimmune cholangitis while female mice had higher lymphocytes infiltration and liver inflammation than males at 11 weeks post-immunization. Besides, apoptosis of cholangiocytes in 2-OA-OVA immunized mice were observed at 3 weeks post-immunization. Furthermore, we collected feces to analyze the gut microbiota of mice. We found the gut microbiota structure altered after immunization. Notably, naïve male mice maintained a protective gut microbiome. We then analyzed the expression levels of toll-like receptors (TLRs), which could recognize microbial components, and found expression levels of TLR7 and TLR9 in bile ducts were significantly upregulated after immunization. To research the impact of alternation of gut microbiota in the PBC pathogenesis, we disturbed the gut microbiota before 5 weeks 2-OA-OVA immunization by feeding mice with non-pathogenic E. coli (DH5α) and found that mice given exogenous bacteria had an increased cell infiltration and decreased protective TLR5 in the liver. Our results suggested that in xenobiotics exposure, dysbiosis of gut microbiota induce apoptosis of cholangiocytes, which led to the initiation of PBC. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T03:29:28Z (GMT). No. of bitstreams: 1 ntu-108-R06424018-1.pdf: 3696901 bytes, checksum: ca764ade4af1141e371cb4926d8f8f64 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 致謝 i
摘要 ii Abstract iii Abbreviation v Content vii Figure content ix Chapter 1 Introduction 1 1.1 Primary biliary cholangitis 2 1.1.1 Innate immune response in PBC 2 1.1.2 Adaptive immune response in PBC 3 1.1.3 Cholangiopathy and apotope 4 1.1.4 Risk factor of PBC 4 1.1.5 Gender-bias in PBC 5 1.2 Gut Microbiota 6 1.2.1 Immune system–microbiome crosstalk 6 1.2.2 Environmental factors and gut microbiota 7 1.2.3 Dysbiosis and immunological disease 8 1.2.4 Microbiota and liver disease 8 1.3 Animal models of PBC 9 1.3.1 Genetically Modified Spontaneous Models 9 1.3.2 Infection Triggered Model 9 1.3.3 Xenobiotic Immunized Animal Models 10 1.4 Specific Aim 10 Chapter 2 Materials and Methods 12 2.1 Experimental Mice 13 2.2 Experimental protocol 13 2.3 Bacterium and intra-gastric administration 13 2.4 Stool sample collection and fecal DNA extraction 14 2.5 Processing and sequencing of bacterial 16s DNA 14 2.6 Detection of serum anti-PDC-E2 antibodies 15 2.7 Histopathology 15 2.8 Cryosection 15 2.9 Immunofluorescence assay and TUNEL assay 16 2.10 Isolation of mRNA and RT-qPCR 16 2.11 Isolation of liver mononuclear cells 17 2.12 Isolation of bile ducts 17 2.13 Cell surface staining 17 2.14 Statistical analysis 18 Chapter 3 Results 19 3.1 Female mice developed higher autoimmune cholangitis than male mice. 20 3.2 Cholangiocytes underwent apoptosis in PBC 21 3.3 Intestinal microbiota structure altered after immunization 21 3.4 Crosstalk between gut microbiota and liver TLRs 22 3.5 Disturbing gut microbiota in PBC murine model 23 Chapter 4 Discussion 25 Figures 30 Reference 42 Appendix 49 | |
dc.language.iso | en | |
dc.title | 以外源物誘發小鼠模式探討原發性膽汁性膽管炎疾病機轉 | zh_TW |
dc.title | Study on the Initiation Mechanisms of Primary Biliary Cholangitis by Xenobiotic Induced Mouse Model | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 江伯倫(Bor-Luen?Chiang),楊雅倩(Ya-Chien Yang),劉兆蓮(Chao-Lien Liu) | |
dc.subject.keyword | 原發性膽汁性膽管炎,自體免疫疾病,外源物,膽管上皮細胞,腸內菌, | zh_TW |
dc.subject.keyword | primary biliary cholangitis,autoimmune disease,xenobiotics,cholangiocytes,microbiota, | en |
dc.relation.page | 50 | |
dc.identifier.doi | 10.6342/NTU201903780 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2019-08-16 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
顯示於系所單位: | 醫學檢驗暨生物技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 3.61 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。